PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.22%
Revenue growth of 2.22% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
0.43%
Gross profit growth of 0.43% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
3.96%
EBIT growth exceeding 1.5x Healthcare median of 0.55%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
4.58%
Operating income growth exceeding 1.5x Healthcare median of 1.71%. Joel Greenblatt would see if unique processes drive exceptional profitability.
3.45%
Net income growth exceeding 1.5x Healthcare median of 1.77%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
3.44%
EPS growth near Healthcare median of 3.80%. Charlie Munger might conclude it’s in line with industry norms.
3.44%
Diluted EPS growth near Healthcare median of 3.81%. Charlie Munger would expect typical industry-level share usage and profit trends.
-0.00%
Share reduction while Healthcare median is 0.11%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.09%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
4.61%
OCF growth exceeding 1.5x Healthcare median of 0.61%. Joel Greenblatt would see if a superior business model or cost structure drives strong cash generation.
4.61%
FCF growth exceeding 1.5x Healthcare median of 1.11%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
24.33%
10Y CAGR of 24.33% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
44.56%
5Y CAGR of 44.56% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
20.69%
3Y CAGR of 20.69% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.06%
Net income/share CAGR of 23.06% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
21.77%
Net income/share CAGR of 21.77% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-8.85%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
138.51%
Equity/share CAGR of 138.51% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
97.30%
5Y equity/share CAGR of 97.30% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
46.99%
3Y equity/share CAGR of 46.99% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
88.89%
5Y dividend/share CAGR of 88.89% while Healthcare is zero. Walter Schloss sees at least some improvement that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
-2.02%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-1.88%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.52%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
1.65%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
73.31%
Slightly rising debt while Healthcare median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.